NF‐κB activation cannot be inhibited with chemotherapy or radiotherapy.16, 17 Therefore, the development of complementary agents which repress NF‐κB signalling may offer therapeutic benefits for patients with glioblastomas. This evidence concerns the gene NFKB1 and glioblastoma.